Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis

MeSH terms

• Antineoplastic Agents, Hormonal* / therapeutic use
• Biomarkers, Tumor* / metabolism
• Breast Neoplasms* / drug therapy
• Breast Neoplasms* / metabolism
• Breast Neoplasms* / pathology
• Female
• Humans
• Ki-67 Antigen* / analysis
• Ki-67 Antigen* / metabolism
• Meta-Analysis as Topic
• Neoadjuvant Therapy*
• Prognosis
• Receptor, ErbB-2* / metabolism
• Receptors, Estrogen* / metabolism